IL110943A - Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders - Google Patents

Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders

Info

Publication number
IL110943A
IL110943A IL11094394A IL11094394A IL110943A IL 110943 A IL110943 A IL 110943A IL 11094394 A IL11094394 A IL 11094394A IL 11094394 A IL11094394 A IL 11094394A IL 110943 A IL110943 A IL 110943A
Authority
IL
Israel
Prior art keywords
inhibitor
treatment
compositions
skin disorders
cholesterol synthesis
Prior art date
Application number
IL11094394A
Other languages
English (en)
Other versions
IL110943A0 (en
Inventor
Naphtali Savion
Sara Brener
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Priority to IL11094394A priority Critical patent/IL110943A/xx
Publication of IL110943A0 publication Critical patent/IL110943A0/xx
Priority to AT95934980T priority patent/ATE321548T1/de
Priority to EP95934980A priority patent/EP0793489B9/en
Priority to KR1019970701625A priority patent/KR970705990A/ko
Priority to CA002199844A priority patent/CA2199844C/en
Priority to CN95195041A priority patent/CN1106841C/zh
Priority to JP51033996A priority patent/JP4128616B2/ja
Priority to AU37173/95A priority patent/AU694274B2/en
Priority to DE69534908T priority patent/DE69534908T2/de
Priority to PCT/US1995/011678 priority patent/WO1996008248A1/en
Priority to BR9509006A priority patent/BR9509006A/pt
Priority to RU97106064/14A priority patent/RU2159611C2/ru
Priority to US08/615,266 priority patent/US5730992A/en
Priority to MXPA97001884A priority patent/MXPA97001884A/es
Publication of IL110943A publication Critical patent/IL110943A/xx
Priority to US08/950,764 priority patent/US6126947A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11094394A 1994-09-13 1994-09-13 Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders IL110943A (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IL11094394A IL110943A (en) 1994-09-13 1994-09-13 Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
MXPA97001884A MXPA97001884A (es) 1994-09-13 1995-09-13 Composiciones para el tratamiento de trastornos enla piel.
JP51033996A JP4128616B2 (ja) 1994-09-13 1995-09-13 皮膚疾患治療用組成物
DE69534908T DE69534908T2 (de) 1994-09-13 1995-09-13 Verwendung von statin zur behandlung von hauterkrankungen
KR1019970701625A KR970705990A (ko) 1994-09-13 1995-09-13 피부 질환 치료용 조성물(Compositions for the Treatment of Skin Disorders)
CA002199844A CA2199844C (en) 1994-09-13 1995-09-13 Compositions for the treatment of skin disorders
CN95195041A CN1106841C (zh) 1994-09-13 1995-09-13 治疗皮肤病的组合物
AT95934980T ATE321548T1 (de) 1994-09-13 1995-09-13 Verwendung von statin zur behandlung von hauterkrankungen
AU37173/95A AU694274B2 (en) 1994-09-13 1995-09-13 Compositions for the treatment of skin disorders
EP95934980A EP0793489B9 (en) 1994-09-13 1995-09-13 Use of statin for the treatment of skin disorders
PCT/US1995/011678 WO1996008248A1 (en) 1994-09-13 1995-09-13 Compositions for the treatment of skin disorders
BR9509006A BR9509006A (pt) 1994-09-13 1995-09-13 Composiçao para aplicaçao tópica na pele composiçao farmacêutica uso de um inibidor de síntese de colesterol e processo para o tratamento mitigaçao ou prevençao de distúrbios de pele
RU97106064/14A RU2159611C2 (ru) 1994-09-13 1995-09-13 Композиции для лечения кожных заболеваний
US08/615,266 US5730992A (en) 1994-09-13 1995-09-13 Compositions for the treatment of skin disorders
US08/950,764 US6126947A (en) 1994-09-13 1997-10-15 Method for the treatment of skin disorders using inhibitor of cholesterol synthesis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11094394A IL110943A (en) 1994-09-13 1994-09-13 Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders

Publications (2)

Publication Number Publication Date
IL110943A0 IL110943A0 (en) 1994-11-28
IL110943A true IL110943A (en) 1997-02-18

Family

ID=11066547

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11094394A IL110943A (en) 1994-09-13 1994-09-13 Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders

Country Status (14)

Country Link
US (1) US6126947A (pt)
EP (1) EP0793489B9 (pt)
JP (1) JP4128616B2 (pt)
KR (1) KR970705990A (pt)
CN (1) CN1106841C (pt)
AT (1) ATE321548T1 (pt)
AU (1) AU694274B2 (pt)
BR (1) BR9509006A (pt)
CA (1) CA2199844C (pt)
DE (1) DE69534908T2 (pt)
IL (1) IL110943A (pt)
MX (1) MXPA97001884A (pt)
RU (1) RU2159611C2 (pt)
WO (1) WO1996008248A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0738510A3 (fr) * 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US5840752A (en) * 1996-11-21 1998-11-24 Henry; James P. Reduction of hair growth
FI972040A (fi) * 1997-05-13 1998-11-14 Nokia Telecommunications Oy Menetelmä pakettivälitteiseen tiedonsiirtoon
WO1999056545A1 (en) * 1998-05-05 1999-11-11 Anwel Saqib R Hair and skin treatment method and composition
FR2801508B1 (fr) * 1999-11-29 2003-11-14 Oreal Utilisation d'inhibiteurs d'hmg coa-reductase pour le traitement de la seborrhee
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
DE10036798A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Mittel zur Behandlung der Haare und der Kopfhaut
CA2445712A1 (en) * 2001-05-31 2002-12-05 Cellegy Pharmaceuticals, Inc. Store operated calcium influx inhibitors and methods of use
US7060729B2 (en) * 2002-09-05 2006-06-13 Reza Babapour Composition and method for treating skin
WO2004026297A1 (ja) * 2002-09-20 2004-04-01 Kowa Co., Ltd. 外用剤
JP4926707B2 (ja) 2003-08-22 2012-05-09 ダニスコ エイ／エス 封入化抗菌材料
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
WO2005094814A1 (ja) * 2004-03-31 2005-10-13 Kowa Co., Ltd. 外用剤
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
US20070015779A1 (en) * 2005-04-29 2007-01-18 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
GB2459922A (en) * 2008-05-13 2009-11-18 Univ Dundee Treatment for keratinizing dermatological disorders by reduction in keratin expression
FR2954124B1 (fr) * 2009-12-18 2012-04-06 Fabre Pierre Dermo Cosmetique Utilisation du 2,3-dihydroxypropyl dodecanoate pour le traitement de la seborrhee
US20120149775A1 (en) * 2010-11-29 2012-06-14 Shiseido Company, Ltd. Methods for preventing and improving skin elastic property loss
US9273192B1 (en) * 2014-11-06 2016-03-01 George Reck Method of preventing microbial growth on water treatment dispersant
WO2017059389A1 (en) * 2015-10-01 2017-04-06 Kythera Biopharmaceuticals, Inc. Compositions comprising a statin for use in methods of adipolysis
AU2017351069B2 (en) 2016-10-24 2019-09-12 Colgate-Palmolive Company Oral care compositions and methods of use
JP2022036341A (ja) * 2018-10-12 2022-03-08 学校法人慶應義塾 慢性皮膚炎の治療のための医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1047235A (pt) * 1963-09-09
GB1026927A (en) * 1964-01-20 1966-04-20 Richardson Merrell Inc Triphenylhaloethylenes
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
GB2081580A (en) * 1980-08-07 1982-02-24 Anand Chaman Lal Sapindus trifoliatus extracts
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US5075327A (en) * 1988-08-10 1991-12-24 Hoffmann-La Roche Inc. Antipsoriatic agents
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
FR2663850B1 (fr) * 1990-07-02 1994-01-14 Gird Galderma Composition pharmaceutique ou cosmetique contenant en association un retinouide et un sterol.
US5466687A (en) * 1992-10-22 1995-11-14 Dr. Karl Thomae Gmbh Arylidene-1-azacycloalkanes and arylalkyl-1-azacyclo-alkanes, their salts, medicaments containing these compounds and their use, and processes for their preparation
DE4303840A1 (de) * 1992-10-22 1994-08-11 Thomae Gmbh Dr K Aryliden-1-azacycloalkane und Arylalkyl-1-azacycloalkane, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
DE4239151A1 (de) * 1992-11-20 1994-05-26 Thomae Gmbh Dr K N,N-Disubstituierte Arylcycloalkylamine, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
IL109037A (en) * 1993-03-19 1999-01-26 Cellegy Pharma Inc Preparations for causing phase separation of lipid layers and preparation of the above preparations
US5730992A (en) * 1994-09-13 1998-03-24 Ramot University Authority For Applied Research And Industrial Development, Ltd. Compositions for the treatment of skin disorders

Also Published As

Publication number Publication date
RU2159611C2 (ru) 2000-11-27
WO1996008248A1 (en) 1996-03-21
JPH10505838A (ja) 1998-06-09
KR970705990A (ko) 1997-11-03
AU3717395A (en) 1996-03-29
JP4128616B2 (ja) 2008-07-30
EP0793489A4 (en) 2001-12-19
MXPA97001884A (es) 2004-04-16
CA2199844A1 (en) 1996-03-21
AU694274B2 (en) 1998-07-16
DE69534908D1 (de) 2006-05-18
DE69534908T2 (de) 2007-01-25
IL110943A0 (en) 1994-11-28
CA2199844C (en) 2007-04-10
EP0793489B1 (en) 2006-03-29
US6126947A (en) 2000-10-03
BR9509006A (pt) 1998-06-23
EP0793489B9 (en) 2006-08-30
CN1106841C (zh) 2003-04-30
EP0793489A1 (en) 1997-09-10
ATE321548T1 (de) 2006-04-15
CN1158567A (zh) 1997-09-03

Similar Documents

Publication Publication Date Title
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
IL121170A0 (en) Compositions for the treatment of dermatological disorders
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
CA2165824A1 (fr) Utilisation du modafinil pour la fabrication d'un medicament ayant un effet sur les apnees du sommeil et les troubles ventilatoires d'origine centrale
IL164568A0 (en) Compounds and methods for the inhibition of the expression of vcam-1
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
EP0909561A3 (en) Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
BG102818A (en) D-manitol and method for its preparation
ZA986673B (en) Use of a combination of an inhibitor of converting enzyme and a diuretic for treating microcirculatory disorders
CA2300405A1 (en) Use of cholinesterase inhibitors for treating attention deficit disorders
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
AU4726797A (en) Prophylactic/remedial agent
BG102667A (en) Diosgenine-containing composition
BG102716A (en) Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline
WO1996031208A3 (de) Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten
MX9700624A (es) Azolidinonas de imidazopiridina.
AU5699396A (en) Compositions for the treatment of skin conditions
HUT75529A (en) Use of dimeticone for treating constipation
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
IL139303A0 (en) Treatment of arthritis and other similar conditions
WO1996026728A3 (en) Use of moxonidine for the treatment of atherosclerosis
MX9709684A (es) Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
UA31995A (uk) Засіб для профілактики і лікування гіпогалактії

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees